Now dispensing BRUKINSA™

November 21, 2019

Now dispensing BRUKINSA™

LOUISVILLE, Ky.–Onco360®, the nation’s largest independent Oncology Pharmacy, has been selected by BeiGene to be a specialty pharmacy network partner for BRUKINSA (zanubrutinib), a new oral treatment for adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.

“The approval of BRUKINSA as a second-line therapy option for patients with relapsed and refractory MCL is an important advancement in fighting this devastating disease,” said Paul Jardina, President and CEO, Onco360. “As a specialty pharmacy dedicated to serving people with cancer, Onco360 is pleased to be one of a few pharmacies bringing this new innovative treatment to MCL patients.”

According to the American Cancer Society, Mantle cell lymphoma is a type of non-Hodgkin’s lymphoma representing 3-10% of all non-Hodgkin’s lymphomas in the United States. By the time it is diagnosed, mantle cell lymphoma has usually spread to the lymph nodes, bone marrow and other organs. In relapsed lymphoma, the disease reappears or grows again after a period of remission, while in refractory lymphoma, the disease does not respond to treatment or responds only briefly.

BRUKINSA is manufactured by BeiGene, a global, commercial-stage, research-based biotechnology company, and was approved by the U.S. Food and Drug Administration (FDA) to treat adult patients with MCL on November 14, 2019. The FDA’s approval of BRUKINSA is based on efficacy results from two single-arm clinical trials, with independent review committee (IRC)-assessed ORR per 2014 Lugano Classification as the primary endpoint. Across both trials, BRUKINSA achieved an ORR, which is the sum of complete responses and partial responses, of 84%. For full prescribing information, visit BRUKINSA.com.